- Companies
- Pangaea Oncology
Pangaea Oncology Valuation Multiples
Pangaea Oncology is valued at $58M as of October 2026, a 3.6x revenue multiple. In the last 12 months, Pangaea Oncology revenue was $17M and Pangaea Oncology EBITDA was ($3M).
Pangaea Oncology Overview
About Pangaea Oncology
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
Founded
2007
HQ
Employees
53
Website
Financials (LTM)
EV
$62M
Valuation Multiples
Start free trialPangaea Oncology Financials
Pangaea Oncology reported last 12-month revenue of $17M and negative EBITDA of ($3M).
In the same LTM period, Pangaea Oncology generated $14M in gross profit, ($3M) in EBITDA losses, and had net loss of ($4M).
Revenue (LTM)
Pangaea Oncology P&L
In the most recent fiscal year, Pangaea Oncology reported revenue of $16M and EBITDA of ($1M).
Pangaea Oncology is unprofitable as of last fiscal year, with gross margin of 99%, EBITDA margin of (7%), and net margin of (25%).
Financial data powered by Morningstar, Inc.
Pangaea Oncology Stock Performance
Pangaea Oncology has current market cap of $58M, and enterprise value of $62M.
Market Cap Evolution
Pangaea Oncology's stock price is $1.61.
Pangaea Oncology share price decreased by 1.3% in the last 30 days, and by 18.5% in the last year.
Pangaea Oncology has an EPS (earnings per share) of $-0.11.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $62M | $58M | 0.2% | -1.3% | -10.3% | -18.5% | $-0.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPangaea Oncology Valuation Multiples
Pangaea Oncology trades at 3.6x EV/Revenue multiple, and (19.3x) EV/EBITDA.
EV / Revenue (LTM)
Pangaea Oncology Financial Valuation Multiples
As of October 17, 2026, Pangaea Oncology has market cap of $58M and EV of $62M.
Pangaea Oncology has a P/E ratio of (13.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pangaea Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Pangaea Oncology Margins & Growth Rates
Pangaea Oncology grew revenue by 20% but EBITDA decreased by 14% in the last fiscal year.
In the most recent fiscal year, Pangaea Oncology reported gross margin of 99%, EBITDA margin of (7%), and net margin of (25%).
Pangaea Oncology Margins
Pangaea Oncology Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Pangaea Oncology Operational KPIs
Pangaea Oncology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Pangaea Oncology's Rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pangaea Oncology's Rule of X is 45% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Pangaea Oncology Competitors
Pangaea Oncology competitors include Bactiguard, Daxor, Lumos Diagnostics Hldgs, K Pharma, Theraclion, Creo Medical Group, Saluda Medical, Osang Healthcare, RenovoRx and Envoy Medical.
Most Pangaea Oncology public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech, DeepTech, B2B SaaS, Vertical SaaS, HealthTech and Longevity.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $22M | $4M | 3.1x | 3.1x | 16.7x | 20.3x | |||
| $10M | - | 5.7x | 6.7x | - | - | |||
| $13M | ($412K) | 3.8x | 3.2x | (122.5x) | (8.9x) | |||
| - | ($6M) | - | - | (7.9x) | - | |||
| $1M | ($7M) | 44.3x | - | (8.8x) | - | |||
| $8M | ($22M) | 7.2x | 5.1x | (2.6x) | (4.1x) | |||
| $90M | ($142M) | 0.5x | 0.4x | (0.3x) | (0.4x) | |||
| $96M | $8M | 0.7x | - | 7.9x | - | |||
This data is available for Pro users. Sign up to see all Pangaea Oncology competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pangaea Oncology
| When was Pangaea Oncology founded? | Pangaea Oncology was founded in 2007. |
| Where is Pangaea Oncology headquartered? | Pangaea Oncology is headquartered in Spain. |
| How many employees does Pangaea Oncology have? | As of today, Pangaea Oncology has over 53 employees. |
| Is Pangaea Oncology publicly listed? | Yes, Pangaea Oncology is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Pangaea Oncology? | Pangaea Oncology trades under PANG ticker. |
| When did Pangaea Oncology go public? | Pangaea Oncology went public in 2016. |
| Who are competitors of Pangaea Oncology? | Pangaea Oncology main competitors include Bactiguard, Daxor, Lumos Diagnostics Hldgs, K Pharma, Theraclion, Creo Medical Group, Saluda Medical, Osang Healthcare, RenovoRx, Envoy Medical. |
| What is the current market cap of Pangaea Oncology? | Pangaea Oncology's current market cap is $58M. |
| What is the current revenue of Pangaea Oncology? | Pangaea Oncology's last 12 months revenue is $17M. |
| What is the current revenue growth of Pangaea Oncology? | Pangaea Oncology revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Pangaea Oncology? | Current revenue multiple of Pangaea Oncology is 3.6x. |
| Is Pangaea Oncology profitable? | No, Pangaea Oncology is not profitable. |
| What is the current EBITDA of Pangaea Oncology? | Pangaea Oncology has negative EBITDA and is not profitable. |
| What is Pangaea Oncology's EBITDA margin? | Pangaea Oncology's last 12 months EBITDA margin is (19%). |
| What is the current EV/EBITDA multiple of Pangaea Oncology? | Current EBITDA multiple of Pangaea Oncology is (19.3x). |
| What is the current FCF of Pangaea Oncology? | Pangaea Oncology's last 12 months FCF is ($5M). |
| What is Pangaea Oncology's FCF margin? | Pangaea Oncology's last 12 months FCF margin is (32%). |
| What is the current EV/FCF multiple of Pangaea Oncology? | Current FCF multiple of Pangaea Oncology is (11.3x). |
| How many companies Pangaea Oncology has acquired to date? | Pangaea Oncology hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Pangaea Oncology has invested to date? | Pangaea Oncology hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Pangaea Oncology
Lists including Pangaea Oncology
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




